Literature DB >> 20851804

Fifty-one Kaposi sarcoma patients.

Mutlu Dogan1, Lutfi Dogan, Feyyaz Ozdemir, Nuriye Yildirim Ozdemir, Hasan Senol Coskun, Ulku Yalcintas Arslan, Guze Ozal, Gungor Utkan, Ahmet Demirkazik, Fazil Aydin, Nurullah Zengin, Fikri Icli.   

Abstract

INTRODUCTION: Kaposi sarcoma (KS) is a mesenchymal tumor originating from lymphatic endothelial cells. Immunosuppressive patients have higher risk for KS. HHV-8 has a role in immunopathogenesis of KS. Aim Evaluation of demographical properties with tumor characteristics and treatment modalities of KS. MATERIAL AND
METHOD: Histopathologically documented KS patients were evaluated retrospectively. Anti-HIV seroprevalence was also evaluated with patient and tumor characteristics besides treatment regimens.
RESULTS: Fifty-one patients were included between September 1998 and February 2009. Male/female ratio was 3.25 (39/12). Median age was 68 (31-94). Lower extremity was the most common site whereas excisional biopsy was the most common diagnostic procedure. Smoking rate was 42.8%. Twenty percent had family history for cancer. Anti- HIV seropositivity rate was 1.9%. Thirty eight percent had local monotherapy, and radiotherapy was most common (26%). Multidisciplinary approach rate was 44%. Most of them had surgery and radiotherapy combination. Two-third of the patients had radiotherapy alone or with other modalities. Rates were as 12% for chemotherapy and 6% for interferon. Vincristine-bleomycin-doxorubicin combination was the most preferred regimen (60%).
CONCLUSION: Male patients in the sixth decade seem to have higher risk for KS. Smoking rate was almost as high. Local therapy might be sufficient in most of the patients. However, we may also consider systemic chemotherapy for selected patients, including vincristine, bleomycin and doxorubicin.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20851804     DOI: 10.1007/s12094-010-0568-7

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  23 in total

Review 1.  Use of liposomal anthracyclines in Kaposi's sarcoma.

Authors:  Susan E Krown; Donald W Northfelt; David Osoba; J Simon Stewart
Journal:  Semin Oncol       Date:  2004-12       Impact factor: 4.929

2.  HLA antigen frequencies in HIV-1-related Kaposi's sarcoma.

Authors:  D L Mann; C Murray; M O'Donnell; W A Blattner; J J Goedert
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

3.  Long-term chemotherapy of HIV-associated Kaposi's sarcoma with liposomal doxorubicin.

Authors:  U R Hengge; S Esser; H P Rudel; M Goos
Journal:  Eur J Cancer       Date:  2001-05       Impact factor: 9.162

Review 4.  Kaposi's sarcoma: an update.

Authors:  Robert A Schwartz
Journal:  J Surg Oncol       Date:  2004-09-01       Impact factor: 3.454

5.  Treatment with taxanes of refractory or life-threatening Kaposi sarcoma not associated with human immunodeficiency virus infection.

Authors:  Laurence Fardet; Pierre-Emmanuel Stoebner; Herve Bachelez; Vincent Descamps; Delphine Kerob; Laurent Meunier; Michel Dandurand; Patrice Morel; Celeste Lebbe
Journal:  Cancer       Date:  2006-04-15       Impact factor: 6.860

6.  Weekly paclitaxel for advanced aggressive classic Kaposi sarcoma: experience in 17 cases.

Authors:  L Brambilla; A Romanelli; M Bellinvia; S Ferrucci; M Vinci; V Boneschi; A Miedico; L Tedeschi
Journal:  Br J Dermatol       Date:  2008-03-20       Impact factor: 9.302

7.  Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma.

Authors:  Hsei-Wei Wang; Matthew W B Trotter; Dimitrios Lagos; Dimitra Bourboulia; Stephen Henderson; Taija Mäkinen; Stephen Elliman; Adrienne M Flanagan; Kari Alitalo; Chris Boshoff
Journal:  Nat Genet       Date:  2004-06-27       Impact factor: 38.330

Review 8.  Targeted therapy for Kaposi sarcoma.

Authors:  Ryan J Sullivan; Liron Pantanowitz; Bruce J Dezube
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

9.  Cutaneous malignancies among HIV-infected persons.

Authors:  Nancy Crum-Cianflone; Katherine Huppler Hullsiek; Elizabeth Satter; Vincent Marconi; Amy Weintrob; Anuradha Ganesan; R Vincent Barthel; Susan Fraser; Brian K Agan
Journal:  Arch Intern Med       Date:  2009-06-22

10.  Risk of Kaposi sarcoma after solid-organ transplantation: multicenter study in 4,767 recipients in Italy, 1970-2006.

Authors:  P Piselli; G Busnach; F Citterio; M Frigerio; E Arbustini; P Burra; A D Pinna; V Bresadola; G M Ettorre; U Baccarani; A Buda; A Lauro; G Zanus; C Cimaglia; G Spagnoletti; A Lenardon; M Agozzino; M Gambato; C Zanfi; L Miglioresi; P Di Gioia; L Mei; G Ippolito; D Serraino
Journal:  Transplant Proc       Date:  2009-05       Impact factor: 1.066

View more
  2 in total

1.  Trends in Kaposi's Sarcoma in Miami Beach from 1987 to 2007.

Authors:  Simon B Zeichner; Ana L Ruiz; Gabriel P Suciu; Rachel Lerner Zeichner; Estelamari Rodriguez
Journal:  ISRN Oncol       Date:  2012-12-25

2.  The Spectrum of Underlying Causes of Iatrogenic Kaposi's Sarcoma in a Large Series: A Retrospective Study.

Authors:  Can Baykal; Tugba Atci; Nesimi Buyukbabani; Armagan Kutlay
Journal:  Indian J Dermatol       Date:  2019 Sep-Oct       Impact factor: 1.494

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.